| 0.4083 -0.008 (-1.92%) | 10-15 12:06 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.48  |
1-year : | 0.51 |
| Resists | First : | 0.41 |
Second : | 0.43 |
| Pivot price | 0.4 |
|||
| Supports | First : | 0.37 |
Second : | 0.31 |
| MAs | MA(5) : | 0.4 |
MA(20) : | 0.4 |
| MA(100) : | 0.36  |
MA(250) : | 0.34 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 43.8 |
D(3) : | 36.8 |
| RSI | RSI(14): 51 |
|||
| 52-week | High : | 0.5 | Low : | 0.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IGC ] has closed below upper band by 46.8%. Bollinger Bands are 46.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.42 - 0.42 | 0.42 - 0.42 |
| Low: | 0.38 - 0.38 | 0.38 - 0.39 |
| Close: | 0.41 - 0.42 | 0.42 - 0.42 |
IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
Wed, 15 Oct 2025
Is IGC Pharma Inc. a candidate for recovery play - July 2025 Setups & Fast Entry Momentum Trade Alerts - newser.com
Wed, 15 Oct 2025
Ranking IGC Pharma Inc. among high performing stocks via tools - July 2025 Update & Free Real-Time Market Sentiment Alerts - newser.com
Wed, 15 Oct 2025
What the charts say about IGC Pharma Inc. today - July 2025 Summary & Daily Stock Trend Reports - newser.com
Wed, 15 Oct 2025
What’s next for IGC Pharma Inc. stock price - Dip Buying & High Accuracy Swing Entry Alerts - newser.com
Tue, 14 Oct 2025
IGC Pharma Expands Alzheimer's Drug Trial with New Research Site - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 76 (M) |
| Shares Float | 69 (M) |
| Held by Insiders | 7.9 (%) |
| Held by Institutions | 21.6 (%) |
| Shares Short | 1,320 (K) |
| Shares Short P.Month | 1,170 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.1 |
| Profit Margin | 0 % |
| Operating Margin | -871.4 % |
| Return on Assets (ttm) | -47.9 % |
| Return on Equity (ttm) | -126.2 % |
| Qtrly Rev. Growth | -51 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.01 |
| EBITDA (p.s.) | -0.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -1.96 |
| PEG Ratio | 0 |
| Price to Book value | 4.09 |
| Price to Sales | 29.24 |
| Price to Cash Flow | -5.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|